Nektar Therapeutics (NKTR) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-111.33M
Depreciation and amortization	11.5M
Stock-based compensation
Other non-cash transactions
Accounts receivable	5.7M
Inventory	592K
Other assets	6.04M
Accounts payable	4.8M
Accrued compensation	9.74M
Accrued expenses
Accrued clinical trial expenses	2.73M
Deferred revenue	-12.67M
Other liabilities	-5.79M
Net cash used in operating activities
Purchases of investments	-142.97M
Sales of investments	4.97M
Maturities of investments	201.45M
Purchases of property and equipment	-3.74M
Net cash (used in) provided by investing activities
Payments of loan and capital lease obligations
Issuance of common stock, net of issuance costs
Net cash provided by financing activities
Effect of exchange rates on cash and cash equivalents	-32K
Net decrease in cash and cash equivalents	7.73M
Cash and cash equivalents at beginning of period	55.57M
Cash and cash equivalents at end of period	63.3M

Entities mentioned with NKTR

View All Entities